What is BioNTech and where is it based?

BioNTech is a Mainz-headquartered biotech that pioneered the mRNA platform behind the Pfizer-BioNTech COVID-19 vaccine. Founded in 2008 by Uğur Şahin and Özlem Türeci, the company's primary focus is now individualized cancer immunotherapy and other mRNA applications. Mainz hosts BioNTech's headquarters, R&D, and manufacturing operations.

TRON gGmbH (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz) is a non-profit translational research institute focused on cancer immunology and gene therapy. It was a key foundation for BioNTech's science before the spinoff. TRON continues operating independently with its own program portfolio.

What sectors are strongest in Mainz biotech?

mRNA therapeutics (BioNTech's pipeline beyond COVID — oncology, infectious diseases, autoimmune), individualized cancer immunotherapy, translational cancer research (TRON), specialty pharmaceuticals (Boehringer Ingelheim's Mainz operations), and university-driven translational biotech via Johannes Gutenberg University Medical Center.

City page

Mainz biotech and pharma directory

Mainz is one of Europe's most globally recognized biotech cities — home to BioNTech, the mRNA platform that delivered the Pfizer-BioNTech COVID-19 vaccine and now drives a deep oncology pipeline. The cluster also includes TRON (Translational Oncology — non-profit translational research institute, where BioNTech's founders Uğur Şahin and Özlem Türeci built the immuno-oncology foundation), Boehringer Ingelheim's Mainz operations, and Johannes Gutenberg University Medical Center. Strong connections to the BioRN Rhine-Neckar cluster (Heidelberg ~80 km south).

Evidence

Visible records3

Verified3

Categories2

Regulated sites2

Avg sources / record0.0

City view

Where does this city read strongest?

Diagnostics (2) and Therapeutics (1). Most visible records: ORGENTEC Diagnostika, Mainz Biomed, and BioNTech SE.

City view

Which standards and public evidence are already visible?

GMP (1), GLP (1), and ISO-13485 (1). Latest review: 22 March 2026. Review cycle: March 2026.

City view

Why does this city matter?

This page brings visible companies and infrastructure records into one practical view of Mainz.

By category

Mainz by category

Jump into a category page filtered to this country only.

Diagnostics (2)Therapeutics (1)

Full list

Mainz biotech and pharma directory

3 city records currently match the active filter.

Mainz diagnostics company focused on autoimmune and infectious-disease testing, with broad immunology assay operations from a German IVD platform.

Lead: Gregoire AllazChief Executive Officer
Scale: Diagnostics platform

Mainz diagnostics company developing molecular screening tests for colorectal and pancreatic cancer from a German diagnostics base.

Lead: Guido BaechlerChief Executive Officer
Scale: Diagnostics platform

Mainz mRNA and immunotherapy headquarters coordinating BioNTech's oncology pipeline, manufacturing network, and clinical execution ahead of the planned 2026 launch window.

Lead: Ugur SahinCEO and Co-Founder
Scale: Commercial Phase

FAQ

Frequently asked questions

What is BioNTech and where is it based?: BioNTech is a Mainz-headquartered biotech that pioneered the mRNA platform behind the Pfizer-BioNTech COVID-19 vaccine. Founded in 2008 by Uğur Şahin and Özlem Türeci, the company's primary focus is now individualized cancer immunotherapy and other mRNA applications. Mainz hosts BioNTech's headquarters, R&D, and manufacturing operations.
What is TRON?: TRON gGmbH (Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz) is a non-profit translational research institute focused on cancer immunology and gene therapy. It was a key foundation for BioNTech's science before the spinoff. TRON continues operating independently with its own program portfolio.
What sectors are strongest in Mainz biotech?: mRNA therapeutics (BioNTech's pipeline beyond COVID — oncology, infectious diseases, autoimmune), individualized cancer immunotherapy, translational cancer research (TRON), specialty pharmaceuticals (Boehringer Ingelheim's Mainz operations), and university-driven translational biotech via Johannes Gutenberg University Medical Center.

Related briefs

Briefs that mention Mainz

Market brief

European mRNA & Immunotherapy Supply Chain 2026

Where the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.

Open brief

Market brief

German Biotech & Pharma Landscape 2026: Heidelberg, Berlin, Mainz

A practical map of the German biotech and pharma landscape in 2026 — 57 operators across Heidelberg, Berlin, Mainz, Hamburg, Munich, and smaller sites, organised by what they actually do and how the pieces connect.

Open brief

Market brief

European Vaccines Landscape 2026: Biodefence, mRNA, Allergen, Infectious Disease

A practical map of the European vaccines sector in 2026 — Bavarian Nordic MVA-BN biodefence, BioNTech and CureVac mRNA, ALK-Abelló allergen immunotherapy, Valneva infectious-disease vaccines, Statens Serum Institut, plus a specialised clinical-stage innovator layer.

Open brief

Next step

Read the city, then widen the view.

Use country and regional pages for wider context, and the company suggestion form for new candidate records.

Open country page Suggest a company